XESM
MLC
Market cap156mUSD
Sep 15, Last price
7.00EUR
1Q
-4.11%
Jan 2017
-42.62%
IPO
-36.65%
Name
Malin Corporation PLC
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
-30.51%
Rev. gr., 5y
8.79%
Revenues
0
Net income
-7m
L+176.00%
CFO
-900k
L-30.77%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Malin Corporation plc operates as a life sciences firm across Ireland and the United States, primarily through its various subsidiaries. The company specializes in developing and delivering vital solutions for critical medical challenges. Its portfolio includes groundbreaking cell and gene therapies aimed at patients with significant unmet medical requirements. Furthermore, Malin provides treatments targeting pressing needs in oncology, infectious diseases, and autoimmune conditions. It also addresses specific women's health concerns, such as recurrent vulvovaginal candidiasis, and offers remedies for fungal nail infections like onychomycosis. Beyond these, Malin's offerings extend to pharmaceutical products for protein misfolding disorders, a sophisticated platform designed to identify pathogenic bacteria within the gut microbiome, and advanced UV-light disinfection technologies. Additionally, it offers corporate secretarial services. Established in 2014, Malin Corporation plc maintains its headquarters in Dublin, Ireland.
Related entities
Subsidiaries
Malin Life Sciences Holdings Limited
Key people
Liam Daniel
Non-Executive Chairman of the Board · since 2019
Neil McLoughlin
General Counsel, Company Secretary
Fiona Dunlevy
Executive Director · since 2023
David Dobrosky
Senior Analyst
Peter Schwartzman
Member of Senior Management Team · since 2016
Luke Corning
Non-Executive Director · since 2020
Jean-Michel Cossery
Non-Executive Director · since 2018
Non-Executive Director · since 2020
Non-Executive Director
Non-Executive Director
Rudy Mareel
Non-Executive Director · since 2018
Non-Executive Director
Headquarters & legal address
The Lennox Building
Richmond Street South
Dublin 2
Dublin, D D02 FK02
IE
Richmond Street South
Dublin 2
Dublin, D D02 FK02
IE
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||